Clinical Trials Logo

Clinical Trial Summary

Congenital heart disease is the most common birth defect affecting mostly 1 in 100 births(1), critical congenital heart disease is when there is low systemic cardiac output which requires urgent surgery or catheter intervention in the first year of life(2), in low-income countries CCHD is associated with severe high mortality rate due to low health resources, in high-income countries, CCHD is associated with life-long morbidities and a high burden on the health care systems(1-3)


Clinical Trial Description

CCHD are classified into three major components: Left heart obstructions representing 30-40%, complete transposition of the great arteries (mostly 30%), and right heart obstructions (20-30%). CCHD may present with signs of low cardiac output and hypoperfusion in case of duct dependent systemic circulation or central cyanosis not responding to oxygen in duct dependent pulmonary circulation or two parallel circulations. Critical congenital heart disease is classified into : - Congenital heart disease with duct-dependent systemic blood flow (SBF) as: 1. Critical aortic stenosis 2. Critical coarctation of the aorta - Congenital heart disease with duct-dependent pulmonary blood flow (PBF) as: 1. Critical pulmonary stenosis. 2. Pulmonary atresia with intact septum. 3. Severe types of Fallot's tetralogy and pulmonary atresia with VSD. - Complete transposition of the great arteries (d-TGA) Classified as non-mixture or inadequate shunting at atrial, ventricular, or duct level. Recent advances in percutaneous neonatal cardiac interventions have improved survival, decreased morbidity, and mortality in newborns with CCHD compared with surgery(4). Pediatric cardiac catheter interventions have been an established way for the management of CCHD(5). Balloon atrial septestomy is the standard intervention for patients with D-TGA with ineffective mixing (6), BAS is indicated when there is time lag between diagnosis and arterial switch operation due to transportation and lack of competent surgical team, and it is also indicated in patients with d-TGA with restrictive inter-atrial communication(7). Ductus arteriosus stenting is used to maintain a reliable source of pulmonary blood flow in patients with duct-dependent cyanotic CHD(5). The main advantage of ductus arteriosus stenting is the avoidance of surgery and shunt-related side effects , also it promotes significant PA growth compared to a BT shunt alone (8). Balloon aortic and pulmonary valvuloplasty and balloon coarctation angioplasty are now established procedures for the management of patients with critical pulmonary or aortic stenosis(9). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05351125
Study type Observational
Source Assiut University
Contact Yomna Hussein Mohammed Hussein Alattar H Alattar, assisstant lec
Phone 01008855990
Email alattaryomna@yahoo.com
Status Not yet recruiting
Phase
Start date June 28, 2022
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03078218 - Health-economic Impact of Pulse Oximetry Systematic Screening of Critical Congenital Heart Disease in Asymptomatic Newborns N/A
Completed NCT04290481 - Oxygen Saturation and Perfusion Index ın Neonates at High Altitude